Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CHM-1 is a small molecule compound described chemically as 2'-fluoro-6,7-methylenedioxy-2-phenyl-4-quinolone. It is a potent, selective antitumor agent shown to induce apoptosis (programmed cell death) in various human cancer cell lines, including hepatocellular carcinoma and ovarian cancer. CHM-1 acts as a vascular disrupting agent and exhibits antiangiogenic properties by inducing apoptosis in human endothelial cells and is noted for upregulating death receptor 5 (DR5) expression via p53 and p38 MAPK pathways, resulting in caspase-dependent apoptotic signaling. Its phosphate prodrug, CHM-1-P, also demonstrates significant antitumor activity in animal models[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chm-1.